Literature DB >> 25819692

Eliglustat for Gaucher's disease: trippingly on the tongue.

Derralynn A Hughes1, Gregory M Pastores2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25819692     DOI： 10.1016/S0140-6736(15)60206-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease.

Authors:  Nathaniel Kleytman; Jiapeng Ruan; Audrey Ruan; Bailin Zhang; Vagishwari Murugesan; Haiqun Lin; Lilu Guo; Katherine Klinger; Pramod K Mistry
Journal:  Mol Genet Metab Rep       Date:  2021-08-28

2.  Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular β-glucosidases.

Authors:  André R A Marques; Mina Mirzaian; Hisako Akiyama; Patrick Wisse; Maria J Ferraz; Paulo Gaspar; Karen Ghauharali-van der Vlugt; Rianne Meijer; Pilar Giraldo; Pilar Alfonso; Pilar Irún; Maria Dahl; Stefan Karlsson; Elena V Pavlova; Timothy M Cox; Saskia Scheij; Marri Verhoek; Roelof Ottenhoff; Cindy P A A van Roomen; Navraj S Pannu; Marco van Eijk; Nick Dekker; Rolf G Boot; Herman S Overkleeft; Edward Blommaart; Yoshio Hirabayashi; Johannes M Aerts
Journal:  J Lipid Res       Date:  2016-01-02       Impact factor: 5.922

Review 3.  Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions.

Authors:  Ken Kok; Kimberley C Zwiers; Rolf G Boot; Hermen S Overkleeft; Johannes M F G Aerts; Marta Artola
Journal:  Biomolecules       Date:  2021-02-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.